Abstract
Notwithstanding improvement of treatment results in ovarian cancer, even the patient who achieved a complete remission may face a relapse. The seven year follow-up figures of the study performed in the Netherlands (1), which compared cisplatin containing combination chemotherapy CHAP-5 (cyclophosphamide, hexamethylmelamine, adriamy-cin and cisplatin) with HexaCAF (hexamethylmelamine, cyclophosphamide, adriamycin and 5-flourouracil) show a steadily decrease of the number of disease free patients upto 60–70% of those formerly in complete remission. Therefore even for patients in complete remission as a result of cisplatin based combination chemotherapy new treatment strategies seem warranted. For the other, not reaching a complete remission this counts the more. Late intensification by an increased dose of cisplatin for instance could offer such a new treatment avenue, based on the theory of Goldie and Coldman (2). Such an increased dose might overcome acquired cisplatin resistance of remaining tumorcells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Neijt, J.P., Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., et al. Randomised trial comparing two combination chemotherapy regimens (HexaCAF vs CHAP-5) in advanced ovarian carcinoma. The Lancet: 594–600, 1984.
Goldie, J.H., Coldman, A.J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep., 63, 1727, 1979.
Piccart, M., Speyer, J., Markman, M., Ten Bokkel Huinink, W.W., Alberts, D., Jenkings, J., Muggia, F. Intraperitoneal chemotherapy: technical experience of five institutions. Semin. Oncol., 12, 90, 1985.
Markman, M., Cleary, S., Lucas, W., Howell, S.B. Intraperitoneal chemotherapy with high dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J. Clin. Oncol., 3, 925, 1985.
Ten Bokkel Huinink, W.W., Van der Burg, M.E.L., Van Oosterom, A.T., Dalesio, O., Rotmensz, N., Vermorken, J.B. Carboplatin replacing cisplatin in combination chemotherapy for ovarian cancer. A large scale randomized phase III trial of the Gynecological Cancer Cooperative Group of EORTC. ASCO abstract for the annual meeting, May, 1987.
Howell, S.B., Pfeifle, C.E., Wang, W.E. et al. Intraperitoneal cisplatin with systemic thiosulphate protection. Cancer Res. 43: 1426–1431, 1983.
Ten Bokkel Huinink, W.W., Dubbelman, R., Aartsen, E., Franklin, H., McVie, J.G. Experimental and clinical results with intraperitoneal cisplatin. Semin. Oncol., 12, 43–46, 1985.
Calvert, A.H. et al. Early clinical studies with cisdiammine-I, I-cyclobutane dicarboxylate platinum. Cancer Chem. Pharmacol., 9, 140, 1982.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Ten Bokkel Huinink, W.W., Vijgh, W.V.D., Dubbelman, R., Heintz, A.P.M., Franklin, H., McVie, J.G. (1988). Platinum Coordination Derivatives by the Intraperitoneal Route: Pharmacokinetics and Clinical Results. In: Nicolini, M. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Developments in Oncology, vol 54. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1717-3_43
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1717-3_43
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8967-8
Online ISBN: 978-1-4613-1717-3
eBook Packages: Springer Book Archive